☰

Adam S. Duerfeldt - Publications

Affiliations: 
2014- Chemistry & Biochemistry University of Oklahoma, Norman, OK, United States 
Area:
Medicinal Chemistry, Organic Chemistry, Chemical Biology
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Dou X, Nath D, Shin H, Nurmemmedov E, Bourne P, Ma JX, Duerfeldt AS. Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders. Journal of Medicinal Chemistry. PMID 32096640 DOI: 10.1021/Acs.Jmedchem.9B01189  0.308
2019 Li Y, Gardner JJ, Fortney KR, Leus IV, Bonifay V, Zgurskaya HI, Pletnev AA, Zhang S, Zhang ZY, Gribble GW, Spinola SM, Duerfeldt AS. First-generation structure-activity relationship studies of 2,3,4,9-tetrahydro-1H-carbazol-1-amines as CpxA phosphatase inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 31104993 DOI: 10.1016/J.Bmcl.2019.05.003  0.405
2018 Lavey NP, Shadid T, Ballard J, Duerfeldt AS. Clostridium difficile ClpP Homologs are Capable of Uncoupled Activity and Exhibit Different Levels of Susceptibility to Acyldepsipeptide Modulation. Acs Infectious Diseases. PMID 30411608 DOI: 10.1021/Acsinfecdis.8B00199  0.364
2018 Dou XZ, Nath D, Shin Y, Ma JX, Duerfeldt AS. Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions. Bioorganic & Medicinal Chemistry Letters. PMID 29628329 DOI: 10.1016/J.Bmcl.2018.03.010  0.395
2018 Que NLS, Crowley VM, Duerfeldt AS, Zhao J, Kent CN, Blagg BSJ, Gewirth DT. Structure based design of a Grp94-selective inhibitor: Exploiting a key residue in Grp94 to optimize paralog-selective binding. Journal of Medicinal Chemistry. PMID 29528635 DOI: 10.1021/Acs.Jmedchem.7B01608  0.669
2017 Li Y, Lavey NP, Coker JA, Knobbe JE, Truong DC, Yu H, Lin YS, Nimmo SL, Duerfeldt AS. Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial Acyldepsipeptides. Acs Medicinal Chemistry Letters. 8: 1171-1176. PMID 29152050 DOI: 10.1021/Acsmedchemlett.7B00320  0.368
2016 Crowley VM, Khandelwal A, Mishra S, Stothert AR, Huard DJ, Zhao J, Muth A, Duerfeldt AS, Kizziah JL, Lieberman RL, Dickey CA, Blagg BS. Development of Glucose Regulated Protein 94-Selective Inhibitors based on the BnIm and Radamide Scaffold. Journal of Medicinal Chemistry. PMID 27003516 DOI: 10.1021/Acs.Jmedchem.6B00085  0.717
2016 Lavey NP, Coker JA, Ruben EA, Duerfeldt AS. Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P. Journal of Natural Products. PMID 26967980 DOI: 10.1021/Acs.Jnatprod.5B01091  0.308
2016 Di XJ, Wang YJ, Han DY, Fu YL, Duerfeldt AS, Blagg BS, Mu TW. Grp94 Delivers γ-aminobutyric Acid Type A (GABAA) Receptors to Hrd1-Mediatd Endoplasmic Reticulum-Associated Degradation. The Journal of Biological Chemistry. PMID 26945068 DOI: 10.1074/Jbc.M115.705004  0.632
2014 Anderson ED, Duerfeldt AS, Zhu K, Glinkerman CM, Boger DL. Cycloadditions of noncomplementary substituted 1,2,3-triazines. Organic Letters. 16: 5084-7. PMID 25222918 DOI: 10.1021/Ol502436N  0.689
2014 Duerfeldt AS, Boger DL. Total syntheses of (-)-pyrimidoblamic acid and P-3A. Journal of the American Chemical Society. 136: 2119-25. PMID 24410439 DOI: 10.1021/Ja412298C  0.536
2014 Duerfeldt AS, Boger DL. ChemInform Abstract: Total Syntheses of (-)-Pyrimidoblamic Acid and P-3A. Cheminform. 45: no-no. DOI: 10.1002/chin.201434217  0.438
2013 Wolfe AL, Duncan KK, Lajiness JP, Zhu K, Duerfeldt AS, Boger DL. A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding. Journal of Medicinal Chemistry. 56: 6845-57. PMID 23944748 DOI: 10.1021/Jm400665C  0.678
2012 Suntharalingam A, Abisambra JF, O'Leary JC, Koren J, Zhang B, Joe MK, Blair LJ, Hill SE, Jinwal UK, Cockman M, Duerfeldt AS, Tomarev S, Blagg BS, Lieberman RL, Dickey CA. Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. The Journal of Biological Chemistry. 287: 40661-9. PMID 23035116 DOI: 10.1074/Jbc.M112.384800  0.661
2012 Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV, Blagg BS. Development of a Grp94 inhibitor. Journal of the American Chemical Society. 134: 9796-804. PMID 22642269 DOI: 10.1021/Ja303477G  0.755
2011 Kusuma BR, Duerfeldt AS, Blagg BS. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry Letters. 21: 7170-4. PMID 22014546 DOI: 10.1016/J.Bmcl.2011.09.073  0.708
2010 Duerfeldt AS, Blagg BS. Hsp90 inhibition: elimination of shock and stress. Bioorganic & Medicinal Chemistry Letters. 20: 4983-7. PMID 20656483 DOI: 10.1016/J.Bmcl.2010.06.108  0.715
2009 Jadhav VD, Duerfeldt AS, Blagg BS. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 6845-50. PMID 19896848 DOI: 10.1016/J.Bmcl.2009.10.091  0.729
2009 Duerfeldt AS, Brandt GE, Blagg BS. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Organic Letters. 11: 2353-6. PMID 19435295 DOI: 10.1021/Ol900783M  0.713
2009 Duerfeldt AS, Blagg BS. Hydrating for resistance to radicicol. Acs Chemical Biology. 4: 245-7. PMID 19371133 DOI: 10.1021/Cb9000712  0.677
Show low-probability matches.